BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management
13 juin 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
Building strong clinical team to effectively support robust clinical programsDr. Burg to leverage his international experience to expand the Company’s clinical trials globally BRANFORD, Conn., June ...
BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
07 juin 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
05 juin 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., June 05, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics and Nektar Therapeutics Present Preclinical Pancreatic Cancer Data for BXCL701, NKTR-214 and Anti-PD1 Combination Therapy at ASCO 2018 Annual Meeting
04 juin 2018 08h30 HE
|
BioXcel Therapeutics, Inc.
BXCL701 in Combination with NKTR-214 and anti-PD-1 Therapy Leads to Complete and Sustained Tumor Regression and Immune Memory in Pre-Clinical Syngeneic Models Results Support Further Development of...
BioXcel Therapeutics to Present at 2018 UBS Global Healthcare Conference
18 mai 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., May 18, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting
17 mai 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., May 17, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
14 mai 2018 16h01 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., May 14, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting
26 avr. 2018 08h30 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., April 26, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics to Ring the NASDAQ Stock Market Opening Bell on April 20, 2018
19 avr. 2018 08h30 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., April 19, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...